120276-47-3

Basic information

• Product Name: Pyridine, 3-(bromomethyl)-5-methyl- (9CI)
• Synonyms: Pyridine, 3-(bromomethyl)-5-methyl- (9CI);3-(Bromomethyl)-5-methylpyridine;3-Bromomethyl-5-methylpyridine;5-Methyl-3-pyridylmethyl bromide;Pyridine, 3-(broMoMethyl)-5-Methyl-
• CAS NO: 120276-47-3
• Molecular Formula: C₇H₈BrN
• Molecular Weight: 186.04912
• EINECS: 1.449 g/cm³
• Product Categories: PYRIMIDINE
• Mol File: 120276-47-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 245℃
• Flash Point: 102℃
• Appearance: Colorless liquid
• Density: 1.448
• Vapor Pressure: 0.045mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Pyridine, 3-(bromomethyl)-5-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 3-(bromomethyl)-5-methyl- (9CI)(120276-47-3)
• EPA Substance Registry System: Pyridine, 3-(bromomethyl)-5-methyl- (9CI)(120276-47-3)

Safety Data

• Hazardous Substances Data: 120276-47-3(Hazardous Substances Data)

Usage

Uses

3-Bromomethyl-5-methylpyridine is an intermediate used to prepare redox-active 5-lipoxygenase inhibitors.

InChI:InChI=1/C7H8BrN/c1-6-2-7(3-8)5-9-4-6/h2,4-5H,3H2,1H3

Upstream product

• 591-22-0 3,5-Lutidine 
• 29681-45-6 5-methylnicotinic acid methyl ester 

Downstream Products

• 158876-82-5 rupatadine 
• 182354-92-3 3-bromo-5-methylpyridine hydrochloride 
• 1384970-94-8 C₁₉H₁₅F₃N₆S 

Relevant articles and documents

Method of preparing rupatadine fumarate through microchannel reaction device

The invention discloses a method of preparing rupatadine fumarate through a microchannel reaction device. A process is optimized on a known path of synthesis for rupatadine fumarate; the microchannelreaction device helps greatly shorten the reaction time and provide high throughput and good product quality stability; high continuity is good for continuous scaled production; operating is simple, safety is high, and separating is easy; the defects of the traditional synthetic path can be effectively overcome; the yield is significantly increased, up to 90%. Desloratadine prepared in the production process is subjected to continuous separation and continuous liquid separation; the solution is added directly to next reaction to obtain rupatadine; the yield is not reduced, and the operation issimplified.

PYRAZOLOPYRIMIDINE DERIVATIVES AND USES AS ANTICANCER AGENTS

Novel compounds having a fused pyrazolopyrimidine derivatives and related fused ring systems are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Pharmaceutical compositions, and methods of using these compounds and compositions to treat cancer and other diseases related to the dysregulation of kinase (such as Aurora A, Aurora B, Aurora C, cMet, JAK2, ROS1, but not limited to) pathways are disclosed. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.

A PROCESS FOR THE PREPARATION OF RUPATADINE

Rupatadine is synthesized by phase transfer catalysed N-alkylation of Desloratadine in biphasic solvent system using aqueous alkali by reaction of a compound of formula (I), with Desloratadine at temperature up to 500C , wherein solvent selected is water immiscible organic solvent. Rupatadine is further converted to Rupatadine fumarate by reaction of Rupatadine in ketonic solvent with an alcoholic solution of fumaric acid.